• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型氟环素 TP-6076 对耐碳青霉烯鲍曼不动杆菌的体外活性。

In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii.

机构信息

Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Germany.

Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.

出版信息

Int J Antimicrob Agents. 2020 Jan;55(1):105829. doi: 10.1016/j.ijantimicag.2019.10.010. Epub 2019 Dec 16.

DOI:10.1016/j.ijantimicag.2019.10.010
PMID:31669740
Abstract

The activity of the novel, fully synthetic fluorocycline antibiotic TP-6076 against carbapenem-resistant Acinetobacter baumannii (CRAB) isolates with defined carbapenem resistance mechanisms was compared against reference antimicrobials with known activity against Acinetobacter spp. The susceptibility of 323 non-duplicate CRAB isolates to TP-6076, amikacin, ampicillin/sulbactam (SAM), cefepime, colistin, doxycycline, eravacycline, imipenem, levofloxacin, meropenem, minocycline, rifampicin, sulbactam, tigecycline, tobramycin and trimethoprim/sulfamethoxazole (SXT) was determined by the broth microdilution method. TP-6076 showed greater activity than comparator antimicrobials of the tetracycline class, SAM, levofloxacin, amikacin, tobramycin, SXT and colistin. MIC and MIC values for TP-6076 were 0.06 mg/L and 0.25 mg/L, respectively. In comparison, doxycycline, eravacycline, minocycline and tigecycline MIC values were 32/≥64, 0.5/1, 4/8 and 1/2 mg/L, respectively. Compared with other compounds, TP-6076 was the most active antimicrobial against CRAB, including isolates that were resistant to other anti-Acinetobacter reference drugs including SAM, colistin, the aminoglycosides amikacin and tobramycin, and levofloxacin. TP-6076 is a promising new agent that may be a useful addition to the limited armamentarium of drugs targeting this problematic pathogen.

摘要

新型全合成氟环素抗生素 TP-6076 对具有明确碳青霉烯类耐药机制的耐碳青霉烯鲍曼不动杆菌(CRAB)分离株的活性与具有已知抗不动杆菌活性的参考抗菌药物进行了比较。采用肉汤微量稀释法测定 323 株非重复 CRAB 分离株对 TP-6076、阿米卡星、氨苄西林/舒巴坦(SAM)、头孢吡肟、多粘菌素、强力霉素、依拉环素、亚胺培南、左氧氟沙星、美罗培南、米诺环素、利福平、舒巴坦、替加环素、妥布霉素和复方磺胺甲噁唑(SXT)的敏感性。TP-6076 对四环素类、SAM、左氧氟沙星、阿米卡星、妥布霉素、SXT 和多粘菌素的活性均优于比较药物。TP-6076 的 MIC 和 MIC 值分别为 0.06 mg/L 和 0.25 mg/L。相比之下,强力霉素、依拉环素、米诺环素和替加环素的 MIC 值分别为 32/≥64、0.5/1、4/8 和 1/2 mg/L。与其他化合物相比,TP-6076 是对 CRAB 最具活性的抗菌药物,包括对 SAM、多粘菌素、氨基糖苷类阿米卡星和妥布霉素以及左氧氟沙星等其他抗不动杆菌参考药物耐药的分离株。TP-6076 是一种很有前途的新型药物,可能是针对这种有问题的病原体的有限药物武器库中的一个有用的补充。

相似文献

1
In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii.新型氟环素 TP-6076 对耐碳青霉烯鲍曼不动杆菌的体外活性。
Int J Antimicrob Agents. 2020 Jan;55(1):105829. doi: 10.1016/j.ijantimicag.2019.10.010. Epub 2019 Dec 16.
2
In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.新型氟环素依拉环素对耐碳青霉烯鲍曼不动杆菌的体外活性。
Int J Antimicrob Agents. 2018 Jan;51(1):62-64. doi: 10.1016/j.ijantimicag.2017.06.022. Epub 2017 Jul 11.
3
Susceptibility profile of and metallo-β-lactamases co-harbouring isolates of carbapenem resistant (CRAB) against standard drugs and combinations.碳青霉烯类耐药鲍曼不动杆菌(CRAB)中同时携带的 及金属β-内酰胺酶的药敏谱分析,对标准药物及联合药物的耐药情况。
Front Cell Infect Microbiol. 2023 Jan 6;12:1068840. doi: 10.3389/fcimb.2022.1068840. eCollection 2022.
4
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].[耐碳青霉烯类鲍曼不动杆菌的耐药机制及体外联合用药的应用]
Zhonghua Shao Shang Za Zhi. 2014 Apr;30(2):166-70.
5
Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.TP-6076 对希腊医院住院患者分离的耐碳青霉烯鲍曼不动杆菌的活性。
Int J Antimicrob Agents. 2018 Aug;52(2):269-271. doi: 10.1016/j.ijantimicag.2018.03.009. Epub 2018 Mar 17.
6
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.多利培南/舒巴坦对全球碳青霉烯类耐药鲍曼不动杆菌分离株的体外活性。
J Antimicrob Chemother. 2020 Sep 1;75(9):2616-2621. doi: 10.1093/jac/dkaa208.
7
In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.碳青霉烯/舒巴坦合剂、多黏菌素、多黏菌素/利福平合剂及替加环素对耐碳青霉烯鲍曼不动杆菌的体外活性
J Antimicrob Chemother. 2007 Aug;60(2):317-22. doi: 10.1093/jac/dkm136. Epub 2007 May 31.
8
Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.多黏菌素 E 联合或不联合美满霉素对不同米诺环素敏感性的碳青霉烯类药物耐药鲍曼不动杆菌的活性。
Microbiol Spectr. 2022 Jun 29;10(3):e0054222. doi: 10.1128/spectrum.00542-22. Epub 2022 Jun 1.
9
In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy.在意大利,替加环素和对照药物对碳青霉烯类敏感和耐药的鲍曼不动杆菌临床分离株的体外活性。
Ann Clin Microbiol Antimicrob. 2008 Feb 8;7:4. doi: 10.1186/1476-0711-7-4.
10
Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China.KBP-7072 对中国收集的 536 株鲍曼不动杆菌复合物的活性。
Microbiol Spectr. 2022 Feb 23;10(1):e0147121. doi: 10.1128/spectrum.01471-21. Epub 2022 Feb 9.

引用本文的文献

1
Carbapenem Resistance in : Mechanisms, Therapeutics, and Innovations.碳青霉烯类耐药性:机制、治疗与创新
Microorganisms. 2025 Jun 27;13(7):1501. doi: 10.3390/microorganisms13071501.
2
Structural analysis of resistance-nodulation cell division transporters.耐药-结节细胞分裂转运蛋白的结构分析。
Microbiol Mol Biol Rev. 2024 Jun 27;88(2):e0019823. doi: 10.1128/mmbr.00198-23. Epub 2024 Mar 29.
3
Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria.替加环素、依拉环素、奥马环素和沙雷环素对快速生长分枝杆菌的抗菌活性。
Microbiol Spectr. 2023 Feb 14;11(1):e0323822. doi: 10.1128/spectrum.03238-22. Epub 2022 Dec 8.
4
Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.耐碳青霉烯类革兰阴性菌感染的流行病学、耐药机制及治疗方案:专家小组意见
Antibiotics (Basel). 2022 Sep 17;11(9):1263. doi: 10.3390/antibiotics11091263.
5
Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Isolates From Greece.舒巴坦-多利培南对来自希腊的全国碳青霉烯类耐药分离株的活性及与其他药物的比较。
Front Cell Infect Microbiol. 2022 Jan 20;11:814530. doi: 10.3389/fcimb.2021.814530. eCollection 2021.
6
An Analysis of the Novel Fluorocycline TP-6076 Bound to Both the Ribosome and Multidrug Efflux Pump AdeJ from Acinetobacter baumannii.分析氟环素 TP-6076 与鲍曼不动杆菌核糖体和多药外排泵 AdeJ 的结合。
mBio. 2021 Feb 22;13(1):e0373221. doi: 10.1128/mbio.03732-21. Epub 2022 Feb 1.
7
The Development of Third-Generation Tetracycline Antibiotics and New Perspectives.第三代四环素类抗生素的发展及新展望
Pharmaceutics. 2021 Dec 5;13(12):2085. doi: 10.3390/pharmaceutics13122085.
8
Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists.鲍曼不动杆菌感染治疗的当代观点:来自传染病药师协会的见解
Infect Dis Ther. 2021 Dec;10(4):2177-2202. doi: 10.1007/s40121-021-00541-4. Epub 2021 Oct 14.
9
Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges.抗微生物药物耐药性的药学方法:前景与挑战
Antibiotics (Basel). 2021 Aug 14;10(8):981. doi: 10.3390/antibiotics10080981.
10
Prevalence of OXA-Type β-Lactamase Genes among Carbapenem-Resistant Clinical Isolates in Thailand.泰国碳青霉烯类耐药临床分离株中OXA型β-内酰胺酶基因的流行情况
Antibiotics (Basel). 2020 Dec 3;9(12):864. doi: 10.3390/antibiotics9120864.